CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
USANewsGroup.com News Commentary VANCOUVER, BC, March 9, 2026 — The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five […]